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The current study was designed to evaluate the pathogenesis, pathology and immune
response of female genital tract infection with Chlamydia trachomatis L2c, the most
recently discovered lymphogranuloma venereum strain, using a porcine model of sexually
transmitted infections. Pigs were mock infected, infected once or infected and re-infected
intravaginally, and samples were obtained for chlamydial culture, gross and microscopic
pathology, and humoral and cell-mediated immunity. Intravaginal inoculation of pigs with
this bacterium resulted in an infection that was confined to the urogenital tract, where
inflammation and pathology were caused that resembled what is seen in human infection.
Re-infection resulted in more severe gross pathology than primary infection, and
chlamydial colonization of the urogenital tract was similar for primary infected and re-
infected pigs. This indicates that primary infection failed to induce protective immune
responses against re-infection. Indeed, the proliferative responses of mononuclear cells
from blood and lymphoid tissues to C. trachomatis strain L2c were never statistically
different among groups, suggesting that C. trachomatis-specific lymphocytes were not
generated following infection or re-infection. Nevertheless, anti-chlamydial antibodies
were elicited in sera and vaginal secretions after primary infection and re-infection,
clearly resulting in a secondary systemic and mucosal antibody response. While
primary infection did not protect against reinfection, the porcine model is relevant for
evaluating immune and pathogenic responses for emerging and known C. trachomatis
strains to advance drug and/or vaccine development in humans.
Keywords: Chlamydia trachomatis, genital infection, immunology, large animal model, lymphogranuloma
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Chlamydia trachomatis is an obligate intracellular bacterial
pathogen that infects annually over 100 million individuals (1).
C. trachomatis comprises two biovars: the trachoma biovar
which includes ocular and urogenital strains and the
lymphogranuloma venereum (LGV) biovar (2, 3). The two
biovars are serologically subdivided into serovars based on the
major outer membrane protein (MOMP) (4). The ocular
serovars A, B, Ba and C are primarily associated with
trachoma, the leading cause of preventable blindness in
developing countries (5). The urogenital (D-K, Da, Ia, and Ja)
and LGV (L1-L3, L2a, L2b, and L2c) serovars cause sexually
transmitted infections. Urogenital infection with serovars D to K,
including Da, Ia, and Ja, can result in cervicitis, urethritis and
post-infection complications such as pelvic inflammatory
disease, ectopic pregnancy, infertility, chronic pelvic pain,
epididymitis and infant pneumonia. The LGV serovars cause a
more invasive disease called lymphogranuloma venereum. After
transiently infecting epithelial cells, these serovars penetrate into
the submucosal tissues to infect macrophages and monocytes
and consequently spread to regional draining lymph nodes (6).
The disease usually manifests as acute inguinal lymphadenitis
with abscess formation (inguinal syndrome) following urogenital
inoculation, whereas anorectal entrance of the bacteria can lead
to acute hemorrhagic proctitis (anorectal syndrome) (7, 8).
Without treatment, persistent infections with chronic
inflammation arise, resulting in strictures and fistulas of the
involved region, which can eventually result in serious
complications such as genital elephantiasis, esthiomene and the
frozen pelvis syndrome with infertility (9, 10).
LGV is endemic in parts of Africa, South-East Asia, South
America and the Caribbean, and has been considered a rare
disease in developed countries until recently (8, 11, 12). Since
2003, LGV outbreaks among men who have sex with men
(MSM) have been reported in Europe (13–19), North America
(20, 21) and Australia (22). Almost all infected men suffered
from severe proctitis, characterized by anorectal pain,
haemopurulent discharge and rectal bleeding, whereas genital
and inguinal symptoms were rare. A high proportion of LGV
patients was also infected with HIV (23). The vast majority of
infections was caused by serovar L2b, which was first identified
in patients from Amsterdam (24). Recently, a new LGV serovar,
called L2c, was isolated from an HIV negative MSM with severe
hemorrhagic proctitis. This hypervirulent serovar appeared to be
a recombinant of C. trachomatis serovars L2 and D (25). The
extent of dissemination of serovar L2c or other LGV
recombinants within the MSM community still have to be
investigated (26). In industrialized countries, LGV is very
uncommon in women, although a few asymptomatic female
patients or those with cervicitis have been described (27, 28).
Recently, the first case of C. trachomatis L2b proctitis in a woman
was reported (29). Furthermore, Verweij et al. (30) described the
first urogenital L2b infection in a female patient with bubonic
LGV. Considering the ongoing outbreaks, LGV infections among
bisexual and heterosexual men as well as heterosexual women are
likely to increase in the near future (30).Frontiers in Immunology | www.frontiersin.org 2Given the importance of LGV infections globally, the purpose
of the current study was to investigate the pathogenesis,
pathology and immune response of vaginal C. trachomatis L2c
infection in a relevant animal model. Previously, Vanrompay
et al. (31) demonstrated that pigs are a suitable animal model to
study female genital tract infection with C. trachomatis serovar E
strains. Pigs are immunologically, genetically and physiologically
more closely related to humans than rodents, and are ethically
and practically more convenient than primates.MATERIALS AND METHODS
Chlamydia trachomatis Strain
C. trachomatis strain L2c was isolated from the rectal mucosa of a
male who had a history of sex with men and suffered from severe
hemorrhagic proctitis (25). Bacteria were propagated in McCoy
cells using standard procedures (32). The tissue culture infective
dose (TCID50) of the C. trachomatis stock was determined by the
method of Spearman and Kaerber (33).
Animals
Fifteen 9-week-old conventionally bred female pigs (Belgian
Landrace) were randomly assigned to three groups of five pigs,
each housed in separate isolation units. The animals were fed ad
libitum with a commercial starting diet. The pigs were
seronegative for Chlamydiaceae as determined by a C. suis
ELISA (34). Nasal, rectal and vaginal swabs did not contain
chlamydial bacteria as determined by culture on McCoy
cells (34).
Experimental Infection and Euthanasia
On day 0, when pigs were 9 weeks old, all groups were
anesthetized by intramuscular injection of Zoletil® 100 (Virbac
Animal Health, Louvain La Neuve, Belgium) in 2% Xylazine-M®
(VMD, Arendonk, Belgium). The control group and the infected
group were inoculated intravaginally with phosphate-buffered
saline (PBS). The re-infected group was infected by intravaginal
injection of 1 x 107 TCID50 of C. trachomatis strain L2c.
Intravaginal inoculation was performed by inserting an
artificial insemination pipette connected to a syringe into the
vagina and injecting 1 ml PBS or 1ml of the bacterial suspension
in PBS. On day 56, the 17-week-old pigs were anesthetized again.
Subsequently, the control group was inoculated with PBS,
whereas the infected group and the re-infected group were
infected intravaginally with C. trachomatis strain L2c (1 x 107
TCID50). At day 77, when pigs were 21 weeks old, all animals
were euthanized by intravenous injection of an overdose of
pentobarbital (70 mg/kg; Nembutal®, Ceva Santé Animale,
Maassluis, the Netherlands) followed by exsanguination. All
animal procedures were in accordance with the guidelines of
the animal care and ethical committee of Ghent University.
Sample Collection and Processing
Vaginal swab samples in 2 ml sucrose-phosphate transport
medium (2-SP) for chlamydial isolation as well as in 2 ml PBSOctober 2020 | Volume 11 | Article 555305
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collected weekly. These samples were stored at -80°C until
tested. Additionally, blood samples (v. jugularis) for antibody
detection were taken weekly. Blood was stored overnight at room
temperature and centrifuged (9300 × g, 20°C, 10 min) to collect
serum. Sera were stored at -20°C until analysis. Peripheral blood
mononuclear cells (PBMC) were isolated at 7 and 10 days post
infection or re-infection to determine their proliferative
responses and immune cell subpopulations.
At euthanasia, the entire body of the pigs was examined for
gross lesions that were scored as none (0), slight (1), moderate (2)
or severe (3). Mononuclear cells (MC) from the spleen, the
cervical lymph node (lymphonodulus cervicalis superficialis) and
the pelvic lymph nodes (the lymphonoduli iliaci mediales, the
lymphonoduli iliaci laterales, the lymphonoduli sacrales and
the lymphonoduli anorectales) were collected to analyze
the proliferative responses and immune cell subpopulations.
Samples of the spleen, liver, pelvic lymph nodes, caecum,
urethra, vagina, cervix, corpus uteri, uterine tubes, oviducts
and ovaries were imbedded in methylcellulose medium, frozen
in liquid nitrogen and stored at -80°C until preparation of
cryostat tissue sections for the detection of C. trachomatis
antigen. Samples from the same tissues were fixed in 10%
phosphate-buffered formalin for histopathology.
C. trachomatis Detection in Swabs
and Tissue Sections
Vaginal swabs in 2-SP were shaken for 1 h at 4°C, centrifuged
(1200 x g, 1 h, 37°C) and 75 µl of the swab content was inoculated
on McCoy cells grown on 13 mm cover slips in Chlamydia Trac
Bottles (International Medical, Brussels, Belgium) using standard
techniques (32). Before the inoculum was added to the cells, they
were washed twice with 1 ml phosphate buffer supplemented
with 0.003% DEAE-dextran. Chlamydial growth was analyzed
using the Mikrotrak direct immunofluorescence staining
(Kordia, Leiden, The Netherlands) at 6 days post inoculation.
Cryostat tissue sections (5 µm) were also stained by use of the
Mikrotrak immunofluorescence test. All slides were examined by
immunofluorescence microscopy (BX41 Olympus, 600×). C.
trachomatis positive cells were counted in five randomly
selected microscopic fields. A score ranging from 0 to 6 was
given for each swab or tissue section. Score 0 indicated that there
were no C. trachomatis inclusion forming units (IFU). Score 1
and 2 indicated a mean of 1 to 5 and 6 to 10 small IFU per
microscopic field, respectively. Score 3 represented more than 10
small IFU and 1 larger IFU per microscopic field. Score 4, 5, and
6 indicated 1 to 5, 6, to 10 and more than 10 larger IFU per
microscopic field, respectively.
Histopathology
Tissue samples were fixed in 10% phosphate-buffered formalin,
dehydrated and embedded in paraffin, sectioned at 5 µm and
stained with hematoxylin and eosin. Slides were examined
blindly by a veterinary pathologist. The microscopic findings
were either graded (none (0), minimal (1), slight (2), moderate
(3), marked (4) or severe (5) histological change) or indicated as
present or absent without a grade.Frontiers in Immunology | www.frontiersin.org 3Serum and Mucosal Antibody Analysis
Sera were heat inactivated at 56°C during 30 min and
subsequently pretreated with kaolin to reduce background
signals in ELISA (35). Vaginal swabs in PBS with protease
inhibitor were shaken for 1 h at room temperature. Isotype-
specific serum and mucosal antibody titers were determined
using a C. trachomatis L2c ELISA. Briefly, Maxisorp 96-well
microtiter plates were coated with purified C. trachomatis strain
L2c EBs (1 × 107 TCID50 per well) diluted in PBS. Plates
were blocked overnight with PBS supplemented with 5% bovine
serum albumin (BSA) at 4°C. Antibody titers were determined
using twofold dilution series in dilution buffer (PBS + 3% BSA +
0.05% Tween®20), starting at a dilution of 1:15. Serum and
swab samples from a previous experimental infection in pigs
(36) were used as positive and negative controls. Antibody
isotype titers were analyzed using monoclonal antibodies
against swine IgA (mAb 27.8.1), IgG (mAb 23.3.1b), and IgM
(mAb 28.4.1) (37) at a dilution of 1:15, 1:20, and 1:50,
respectively, followed by an 1:5,000 dilution of biotinylated
anti-mouse IgG (H+L) (Dako, Glostrup, Denmark).
Subsequently, the plates were incubated with 1:2500 diluted
peroxidase-labeled streptavidin (Zymed Laboratories, San
Francisco, USA). Finally, the substrate and chromogene
ABTS (2, 2’-Azino-di(3-ethylbenzthiazoline-6-sulfonate);
KPL, Maryland, USA) was added. Antibody titers were
defined as the inverse of the highest sample dilution giving an
absorbance value at 405 nm above the cut-off value (mean
absorbance of seronegative pig serum at a dilution of 1:15 +
twice the standard deviation).
PBMC and MC Proliferation Assay
At 7 and 10 days post infection or re-infection, PBMC were
isolated from heparinized blood samples collected from the
jugular vein by density gradient centrifugation (500 × g, 18°C,
25 min) on Lymphoprep™ (Axis-Shield, Oslo, Norway).
Subsequently, the erythrocytes were lysed with ammonium
chloride. After centrifugation (270 × g, 4°C, 10 min), the cells
were washed and resuspended in leukocyte medium (RPMI-1640
(Life Technologies, Merelbeke, Belgium) supplemented with 5%
heat-inactivated fetal calf serum (Life Technologies), 5×10−5 M
b-mercaptoethanol (Life Technologies), 1% non-essential amino
acids (Life Technologies), 1% sodium pyruvate (Life
Technologies), 1% L-glutamine (Life Technologies), 1%
penicillin-streptomycin and 1% kanamycin).
At euthanasia, mononuclear cells (MC) were isolated from the
spleen, the cervical lymph node (cervicalis superficialis) and the
pelvic lymph nodes (iliaci mediales, iliaci laterales, sacrales and
anorectales). Isolation of MC was performed by mincing the
tissues, after removal of the surrounding fat. Erythrocytes were
lysed with NH4Cl solution and the cells were washed and
subsequently resuspended in leukocyte medium without b-
mercaptoethanol. PBMC or MC were placed in 96-well tissue
culture plates at a concentration of 5 × 105 cells per well.
Proliferative responses were tested by adding 105 C. trachomatis
purified L2c EBs, 10 µg concanavalin A (ConA) (positive control)
or medium (negative control) to the wells. Each condition was
tested in duplicate. The cells were incubated at 37°C in aOctober 2020 | Volume 11 | Article 555305
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proliferation was measured by incorporation of 1 µCi/well of 3H-
thymidine (Amersham ICN, Bucks, UK) for the last 16 h of a 3-
day or 4-day culture period, respectively. Cells were harvested onto
glass fiber filter strips (Perkin Elmer, Life Science, Oosterhout, The
Netherlands) with a cell harvester (Skatron, Liers, Norway) and
radioactivity was measured with a b-scintillation counter (Perkin
Elmer). As a measure of proliferative response, stimulation indices
(SI) were calculated as the ratio of the mean counts per minute of
stimulated PBMC or MC versus the mean counts per minute of the
negative control.
Flow Cytometric Analysis of Immune Cell
Subpopulations
The immune cell subpopulations in the blood, the spleen, the
cervical and pelvic lymph nodes were examined by flow
cytometry. T cell populations (CD3+CD4+CD8-, CD3+CD4-
CD8+, CD3+CD4+CD8+, CD3+CD4-CD8-, T cells with a gd T
cell receptor), B cells (MHCII+CD21+, MHCII+IgM+),
monocytes (MHCII+SWC3+), NK cells (CD3-CD4-CD8+) and
plasmacytoid dendritic cells (pDC) (CD3-CD4+CD8-) were
analyzed. For the lymphoid tissues the CD3-CD4+CD8-
population does not exist entirely of pDC, but also contains an
unknown lineage, presumably of myeloid origin (38). It was
impossible to distinguish between both populations based on the
used markers. PBMC and MC (106 cells) were incubated for
20 min at 4°C in staining buffer (RPMI-1640 + 1% heat-
inactivated FCS) with optimal concentrations of monoclonal
antibodies (Supplementary Table 1). Cells stained with
isotype-matched irrelevant mAbs were used as a negative
control. After incubation, the cells were washed with staining
buffer and stained with the appropriate isotype-specific Alexa-
647-, FITC-, or PE- conjugated antibodies (Life Technologies)
for 20 min at 4°C. Cells were washed twice and resuspended in
PBS. Data were acquired on a FACSCanto flow cytometer
(Beckton Dickinson, Erembodegem, Belgium) with a minimum
event count of 50 000 and analyzed with FACSDiva® software.
Doublets were excluded based on FSC-H/FSC-A and SSC-H/
SSC-A plots.
Statistical Analysis
Statistical analyses were performed using SPSS 22. The non-
parametric Mann-Whitney U test was used to analyze differences
between two groups. Results were considered significantly
different if P<0.05.RESULTS
Gross Lesions
Supplementary Table 2 shows the median scores for gross
lesions in the infection and the re-infected group, determined
at necropsy. Gross lesions were absent in all pigs of the control
group. Gross pathology was generally more severe for the re-
infected group than for the infected group, especially in the urogenital
tract. All re-infected pigs showed congestion of the urogenital tractFrontiers in Immunology | www.frontiersin.org 4(Figure 1), while only three pigs (60%) of the infected group had a
congested urogenital tract. A significantly higher congestion of the
uterus, uterine tubes, ligamentum latum uteri, mesovarium and
urethra was noticed in the re-infected group than in the control
and/or the infected group. A large amount of clear watery exudate
was present in almost the entire genital tract of 40% of the pigs of both
infected groups and in the uterus of one animal (20%) of the re-
infected group (Figure 1). The liver of two re-infected pigs (40%) was
moderately congested, whereas the liver was normal in all animals of
the infected group. Gross pathology was detected in the spleen of
three pigs (60%) of the infected group and four pigs (80%) of the re-
infected group (Figure 1). The pelvic lymph nodes were moderately
to severely enlarged in all animals of both infected groups.
Furthermore, moderate to severe congestion of the pelvic lymph
nodes was detected in 80% of the pigs of both infected groups (Figure
1). Gross lesions in the pelvic lymph nodes were significantly different
between the control group and both infected groups.
Histopathology
The median scores of the histopathological lesions detected in the
urogenital tract of the pigs are presented in Supplementary Table
3. Statistical differences among groups were only present in the
cervix, the corpus uteri, the uterine horns and the urethra. In the
cervix and the uterine horns, interepithelial inflammatory cells had
increased slightly in the mucosa of the infected group (Figure 2).
Furthermore, epithelial vacuolation was noted in the cervix,
corpus uteri and uterine horns of the infected group (Figure 2).
This vacuolation was to a lesser extent also present when animals
were re-infected. The significantly higher median score for
epithelial vacuolation in the urethra of the re-infected group was
due to the absence of the mucosa in some samples and the high
value in one animal. In the oviducts, exfoliated epithelial cells and
proteinaceous fluid were observed only in both infected groups,
however with low incidence and/or severity. The lesions noticed in
the oviducts and the vagina were not statistically different among
groups. No histopathological lesions were observed in the ovaries.
In the liver of one or two animals of each group minimal to slight
focal to multifocal mononuclear inflammations within the
parenchyma or portal areas were noted. This lesion is
considered to be a background lesion, frequently observed and
unrelated to the experimental infection. The liver samples from
the other pigs and all spleen, caecum and pelvic lymph node
samples showed no microscopic lesions.
Chlamydia trachomatis Vaginal Excretion
Vaginal swabs were examined for the presence of viable C.
trachomatis using culture in McCoy cells. Median culture scores
for vaginal swabs of the infection and the re-infected group,
collected at different time points post infection, are presented in
Supplementary Table 4. All vaginal swab samples of the control
group were Chlamydiaceae negative, as were the swabs of the other
pigs taken before primary infection. The infected group vaginally
excreted C. trachomatis from day 59, three days after primary
infection of this group, onwards. In the re-infected group, vaginal
C. trachomatis shedding was consistently high from day 3 to day
49 post primary infection and was slightly decreased at day 56 and
day 59. Median culture scores were again consistently high fromOctober 2020 | Volume 11 | Article 555305
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56, vaginal shedding in the re-infected group was significantly
higher than in the control group and the infected group, which
was not yet infected at these time points. After primary infection of
the infected group, the median excretion scores of the infected
group and the re-infected group did not differ statistically from
each other, but were significantly higher than those of the
control group.
C. trachomatis Detection in Tissue
Sections
Table 1 shows the median scores for the presence of C.
trachomatis in tissues of the infection and the re-infectedFrontiers in Immunology | www.frontiersin.org 5group at euthanasia. All tissue samples from the control
group were negative. C. trachomatis was neither detected in
the caecum, the spleen, the liver and the pelvic lymph nodes of
both infected groups. Chlamydial EBs and intracellular
inclusions, containing replicating chlamydiae, were detected
in both the lower and upper genital tract tissues of all pigs of the
infected and the re-infected group. Thus, an ascending C.
trachomatis infection occurred in all pigs of both infected
groups. Furthermore, chlamydial replication was observed in
the urethra of three pigs (60%) of the infected group and two
pigs (40%) of the re-infected group. The urethra of the
remaining infected animals contained only elementary bodies,




FIGURE 1 | Gross lesions in the re-infected group. (A) The oviducts were dilated by the presence of serous exudate in their lumen (arrow a). Hyperemia of the
mesovarium and mesosalpinx (arrow b). (B) Hyperemia of the lig. latum uteri (arrow c), the mesovarium and mesosalpinx (arrow (d) and the uterine tubes (arrow e).
(C) Hyperemia of the cervical mucosa (arrow f). A large amount of serous exudate was detected in the lumen of the vagina, cervix, corpus uteri and uterine tubes.
Note the severely dilated uterine tube (arrow g). (D) The spleen is enlarged, hemorrhagic (arrow h) and shows expansion of the red pulp (arrow i). (E) Enlarged and
hemorrhagic pelvic lymph nodes.October 2020 | Volume 11 | Article 555305
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significantly higher for the infected and the re-infected group
than for the control group. Statistical analysis revealed noFrontiers in Immunology | www.frontiersin.org 6significant differences between the median scores of both
infected groups.
Serum and Mucosal Antibody Responses
Tables 2 and 3 show the C. trachomatis L2c-specific IgM, IgG and
IgA antibody titers in sera and vaginal secretions collected at
different time points post infection or re-infection. Chlamydial
antibodies were never detected in the serum and vaginal swab
samples of the control pigs. The pigs of the infected and the re-
infected group neither had serum or vaginal C. trachomatis-specific
antibodies before they were infected. Serum IgM, IgG and IgA
antibodies were elicited from 7 days post primary infection onwards
and peak titers were reached at 14 or 21 dpi. Anti-chlamydial IgM
and IgA were observed in serum samples until 21 and 28 days post
primary infection, respectively. Serum IgG antibodies, on the other
hand, remained detectable throughout the experiment in most pigs.
C. trachomatis L2c-specific serum IgM, IgG, and IgA titers
increased again following re-infection. Serum IgA titers reached
peak levels early after re-infection (7 days), whereas serum IgM and
IgG titers continued to increase until the end of the experiment.
Vaginal secretions were positive for anti-chlamydial IgM, IgG and
IgA from 14 to 21, 14 to 28, and 7 to 21 days post primary infection,
respectively. Mucosal antibodies appeared again from 7 (IgM and
IgG) or 14 (IgA) days post re-infection onwards. Re-infection
clearly resulted in a secondary systemic and mucosal antibodyFIGURE 2 | Photomicrographs of uterine horn tissue sections stained with hematoxylin and eosin. Original magnification ×10 (A, C) or ×40 (B). (A) Minimal
lymphocytic infiltration in the lamina propria (arrow a) of a control animal. (B, C) Inflammation of the uterine horns of an animal of the infected group. Note the
interepithelial lymphocytic infiltration (arrow b), the vacuolation of the epithelium (arrow c), the oedema in the lamina propria (arrow d) and the lymphocytic infiltration in
the lamina propria (arrow e).TABLE 1 | Presence of C. trachomatis in tissues of the infected and the re-
infected group at euthanasia#.
Tissue Median score* (range) in:
Infected group Re-infected group
Vagina 3 (3-4)a 3 (1-3)b
Cervix 3 (3-4)a 3 (3-3)b
Corpus uteri 3 (2-4)a 3 (3-4)b
Uterine horn R 3 (3-4)a 3 (1-4)b
Uterine horn L 3 (3-4)a 3 (3-5)b
Oviduct R 3 (3-3)a 3 (3-4)b
Oviduct L 3 (3-4)a 3 (1-4)b
Ovary R 3 (3-3)a 3 (0-4)b
Ovary L 3 (3-3)a 3 (1-4)b
Urethra 3 (1-4)a 1 (0-3)b#The median score (range) in the control group was 0 (0-0) for all tissues.
*C. trachomatis positive cells were counted in five randomly selected microscopic fields.
Score 0: no C. trachomatis positive cells; Score 1: 1–5 EBs and no inclusions; Score 2: 6–
10 EBs and no inclusions; Score 3: >10 EBs and 1 inclusion-positive cell; Score 4: 1–5
inclusion-positive cells; Score 5: 6–10 inclusion-positive cells; Score 6: >10 inclusion-
positive cells.
aP < 0.05 for a comparison of the control group and the infected group.
bP < 0.05 for a comparison of the control group and the re-infected group.
cP < 0.05 for a comparison of the infected group and the re-infected group.October 2020 | Volume 11 | Article 555305
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IgG and IgA titers than following primary infection.
PBMC and MC Proliferation
At 7 and 10 days post primary infection or re-infection,
proliferative responses of PBMC to C. trachomatis strain L2c
were measured. Furthermore, proliferation of spleen, cervical
and pelvic lymph node MC was determined at euthanasia.
Surprisingly, the proliferative activities of PBMC and MC were
never statistically different among groups (data not shown). The
proliferative responses to ConA were always positive indicating
the viability of the cells and the functionality of the assay.
Immune Cell Subpopulations
Flow cytometry was used to identify blood immune cell
subpopulations at 7 and 10 days post primary infection or re-Frontiers in Immunology | www.frontiersin.org 7infection (Figure 3). Seven days after primary infection of the re-
infected group, the median percentage of NK cells was
significantly higher for the re-infected group than for the
infected group. Three days later, the re-infected group had
significantly higher median percentages of T cells, gd T cells
and NK cells than the non-infected animals. At day 63, 7 days
after primary infection of the infected group and re-infection of
the re-infected group, a significantly higher median percentage of
gd T cells was noticed in both infected groups than in the control
group. Within total T cells, significantly fewer CD4-CD8+ T cells
were detected in the re-infected group than in the control group.
Moreover, the re-infected animals had significantly lower
median percentages of B cells and monocytes than the other
groups. At day 66, the re-infected group had significantly lower
median percentages of T cells and IgM+ B cells, but a significantly
higher median percentage of plasmacytoid dendritic cells (pDC)TABLE 2 | C. trachomatis L2c-specific IgM, IgG, and IgA serum antibody titers of the infected (I) and the re-infected (R) group#.
Dpi Procedure Median titer (range) for:
Serum IgM Serum IgG Serum IgA
Infected group Re-infected group Infected group Re-infected group Infected group Re-infected group
0 Infection R 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
7 0 (0-0)c 60 (30-60)b,c 0 (0-0)c 60 (30-60)b,c 0 (0-0) 0 (0-15)
14 0 (0-0)c 480 (120-480)b,c 0 (0-0)c 240 (120-240)b,c 0 (0-0)c 60 (60-60)b,c
21 0 (0-0)c 240 (60-240)b,c 0 (0-0)c 120 (60-120)b,c 0 (0-0)c 30 (30-60)b,c
28 0 (0-0) 0 (0-0) 0 (0-0)c 30 (30-60)b,c 0 (0-0)c 30 (15-30)b,c
35 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-30) 0 (0-0) 0 (0-0)
42 0 (0-0) 0 (0-0) 0 (0-0)c 30 (0-30)b,c 0 (0-0) 0 (0-0)
49 0 (0-0) 0 (0-0) 0 (0-0)c 30 (0-60)b,c 0 (0-0) 0 (0-0)
56 Infection I & R 0 (0-0) 0 (0-0) 0 (0-0)c 30 (0-60)b,c 0 (0-0) 0 (0-0)
63 60 (30-60)a 30 (30-60)b 30 (30-60)a,c 120 (60-240)b,c 0 (0-15)c 120 (60-120)b,c
70 480 (120-480)a,c 60 (30-60)b,c 120 (120-240)a,c 480 (120-480)b,c 15 (15-15)a,c 30 (30-30)b,c
77 Euthanasia 120 (60-120)a 60 (60-120)b 240 (240-480)a,c 960 (480-1920)b,c 30 (30-30)a,c 15 (15-15)b,cOctober 2020 | Volume#The median IgM, IgG, and IgA serum antibody titers (range) in the control group were 0 (0-0) for all time points.
aP < 0.05 for a comparison of the control group and the infected group.
bP < 0.05 for a comparison of the control group and the re-infected group.
cP < 0.05 for a comparison of the infected group and the re-infected group.TABLE 3 | C. trachomatis L2c-specific IgM, IgG, and IgA vaginal secretion antibody titers of the infected (I) and the re-infected (R) group#.
Dpi Procedure Median titer (range) for:
Mucosal IgM Musocal IgG Mucosal IgA
Infected group Re-infected group Infectedgroup Re-infected group Infected group Re-infected group
0 Infection R 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
7 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)c 15 (0-30)b,c
14 0 (0-0)c 60 (30-60)b,c 0 (0-0)c 60 (30-60)b,c 0 (0-0)c 15 (0-15)b,c
21 0 (0-0)c 30 (15-30)b,c 0 (0-0)c 120 (30-120)b,c 0 (0-0) 0 (0-0)
28 0 (0-0) 0 (0-0) 0 (0-0)c 15 (0-30)b,c 0 (0-0) 0 (0-0)
35 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
42 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
49 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
56 Infection I & R 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
63 0 (0-0)c 30 (30-30)b,c 0 (0-0)c 60 (30-60)b,c 0 (0-0) 0 (0-0)
70 60 (60-60)a,c 15 (0-30)b,c 60 (30-60)a,c 120 (120-120)b,c 15 (0-15)a,c 30 (30-30)b,c
77 Euthanasia 0 (0-30) 0 (0-0) 120 (60-120)a,c 60 (60-60)b,c 0 (0-15)c 30 (30-60)b,c#The median IgM, IgG, and IgA mucosal antibody titers (range) in the control group were 0 (0-0) for all time points.
aP < 0.05 for a comparison of the control group and the infected group.
bP < 0.05 for a comparison of the control group and the re-infected group.
cP < 0.05 for a comparison of the infected group and the re-infected group.11 | Article 555305
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cells and gd T cells were significantly higher for the infected
group than for the control group. Furthermore, significantly
lower median percentages of mature B cells and monocytes were
observed in both infected groups than in the control group. At
euthanasia, immune cell populations in the spleen, cervical and
pelvic lymph nodes were also determined using flow cytometry
(Figure 3). For the spleen, significantly higher median
percentages of CD4+CD8- T cells and CD3-CD4+CD8- MC,
containing pDC, besides a significantly lower median
percentage of total T cells were detected in the non-infected
animals. The re-infected group had a significantly higher median
percentage of NK cells in the spleen than the control group.
Furthermore, a significantly lower percentage of monocytes was
present in the spleen of the infected group as compared to the
other groups. For the cervical lymph nodes, significantly lower
median percentages of CD4-CD8+ T cells and mature B cells
were noticed in the infected group than in the control and the re-
infected group, respectively. For the pelvic lymph nodes, the re-
infected pigs had a significantly lower median percentage of B
cells and a significantly higher median percentage of NK cells.
Within total T cells, significantly more CD4-CD8- T cells were
observed in both infected groups than in the control group.DISCUSSION
Since 2003, an ongoing outbreak of LGV has been observed among
MSM in developed countries (13–22). There have only been a few
anecdotal reports of LGV urogenital and rectal infections among
women. However, this may change in the near future due to
dissemination of the disease to bisexual men and to women (30).
While initial infection in the cervix may more likely be
asymptomatic compared to rectal infections in males and thus
remain untreated, both men and women develop serious
complications from LGV infections. Because the porcine model
represents an appropriate model for studying human C. trachomatisFrontiers in Immunology | www.frontiersin.org 8strains (31), the present study aimed to obtain more knowledge
about the pathogenesis, pathology and immune response of female
genital tract infection and re-infection with C. trachomatis L2c, the
most recently discovered LGV strain (31).
At necropsy, gross pathology was generally more severe for the
re-infected pigs than for animals infected only once. In women,
repeated urogenital C. trachomatis infections are also associated
with an elevated risk of pathological damage resulting in
reproductive complications, such as pelvic inflammatory disease,
ectopic pregnancy and infertility (39–43). Similar levels of C.
trachomatis EBs and intracellular inclusions were detected in the
lower and upper genital tract tissues of the infection and the re-
infected group. This indicates thatC. trachomatis L2c could colonize
the urogenital tract following re-infection as efficiently as following
primary infection. Thus, the primary infection failed to induce
protective immune responses against re-infection. Several
epidemiologic studies of humans indicate that protective
immunity to re-infection, albeit only partial, develops following
prior genital infection with C. trachomatis, including LGV strains
(44–49). These findings are consistent with those from murine and
non-human primate model experiments (50–52).
In our study, the infection was confined to the urogenital tract
with infection of the tissues from the vagina to the ovaries and
including the urethra. There was no evidence of chlamydial
bacteria in the caecum, spleen, liver, and pelvic lymph node
samples of the infected animals. This is in accordance with the
symptoms observed in the patient from which L2c was isolated
(25). The patient suffered from severe localized mucosal disease,
namely hemorrhagic proctitis, and did not show an inguinal
syndrome, indicating that the bacteria had not spread to the
inguinal lymph nodes. This lack of dissemination to regional
lymph nodes was likely due to the presence of a functional
cytotoxin, which probably enables innate immune evasion (53,
54). The toxin gene was presumably acquired from a D strain,
since all other LGV strains to date lack this gene (25).
Infection of the female porcine genital tract with C. trachomatis
serovar L2c resulted only in minor microscopic lesions, in particularFIGURE 3 | Median percentage of different subpopulations within total T cells (CD3+), isolated at 7 and 10 days post infection or re-infection, and in spleen, cervical
and pelvic lymph nodes at euthanasia. T cells were divided into four subpopulations based on the expression of CD4 and CD8. For each time point or tissue,
different letters within a data series are significantly different (P<0.05). C: control group; I: infected group; R: re-infected group.October 2020 | Volume 11 | Article 555305
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in contrast with a previous study describing genital tract infection of
female pigs with twoC. trachomatis serovar E strains (31). However,
samples in the present study and the study by Vanrompay et al.,
(31) were not taken at the same time point post infection and the
infection schedule was different. Remarkably, histopathological
changes were more prominent in the genital tissues of the
infected group than the re-infected group, which is opposed to
the gross pathology noticed in both groups. Immunohistochemistry
could provide more detailed information on the cells involved in the
microscopic lesions and therefore will be performed during future
C. trachomatis experiments in pigs.
All infected animals vaginally excreted C. trachomatis from three
days post infection onwards. Prior infection had no influence on
vaginal chlamydial shedding, since similar excretion levels were
observed after primary infection and re-infection. Vaginal excretion
was consistently high until 49 days post primary infection and was
only slightly decreased at day 56, indicating that the pigs had not yet
resolved the chlamydial infection after 8 weeks. In a future
experiment, some animals will be kept longer, monitoring
bacterial excretion twice a week to find out if the infection will be
cleared. In humans, C. trachomatis infection can last several months
before spontaneous clearance (55–57). In some patients infected
with LGV serovars, the bacteria could still be isolated many years
after the primary infection (58, 59).
Anti-chlamydial IgM, IgG and IgA antibodies were elicited in
sera and vaginal secretions following primary infection with C.
trachomatis L2c. Re-infection clearly resulted in a secondary
systemic and mucosal antibody response, with significantly lower
IgM titers and significantly higher IgG and IgA titers than following
primary infection. However, the induced antibody response was not
able to even partially protect the pigs against re-infection. The
importance of antibodies in immunity to C. trachomatis is still
disputed. In women, the amount of IgA in cervical secretions was
found to correlate inversely with the amount of C. trachomatis
recovered from the cervix (60). However, high titers of C.
trachomatis-specific serum IgG antibodies were not associated
with resolution of infection in women, but with increased severity
of post-infection complications (61). In mice, antibodies are not
needed to resolve a primary genital C. muridarum infection (62),
but contribute to protection against re-infection (63). In the guinea
pig model, antibodies play an important role in immunity to both
primary infection and re-infection with Chlamydia caviae (64, 65).
Interestingly, it was shown that C. trachomatis strains of the LGV
biovar are more resistant to neutralization by immune sera than
strains of the trachoma biovar (66), which may explain the lack of
protection on re-infection in our study.
The proliferative responses of PBMC and MC to C. trachomatis
strain L2c were never statistically different among groups, suggesting
that C. trachomatis-specific lymphocytes were not generated
following infection or re-infection. However, anti-chlamydial
antibodies were detected, which implies that C. trachomatis-specific
B lymphocytes must have been created at a certain point.
Simultaneously with the proliferation assays, the immune cell
subpopulations within PBMC and lymphoid tissue MC were
analyzed. The observed differences in percentages of B and TFrontiers in Immunology | www.frontiersin.org 9lymphocytes among groups are considered irrelevant, since no
C. trachomatis-specific lymphocytes appeared to be present at the
examined time points. Furthermore, the differences in percentages of
monocytes, NK cells and pDC between groups were sometimes
inconsistent. Primary infection of the re-infected group resulted in a
significant increase of NK-cells in the blood, whereas this was not the
case following primary infection of the infected group. However, both
the spleen and the pelvic lymph nodes of the re-infected animals
contained significantly higher percentages of NK cells three weeks
post re-infection. NK cells are an important component of the innate
immune response, which can help control chlamydial infections by
secreting IFN-g (67). Moreover, it was shown that human NK cells
are able to lyse epithelial cells infected with C. trachomatis (68).
Nevertheless, an effective protective immune response to genital
C. trachomatis infections is highly dependent on specific CD4+ T-
helper Type 1 cells (69–71), but also on IFN-g (72, 73). The apparent
lack of C. trachomatis-specific T cells following infection or re-
infection in the present study can explain why the pigs were not
even partially protected against re-infection. However, the immune
responses detected in the blood, the spleen, and cervical and pelvic
lymph nodes do not necessarily mirror the immune responses
elicited at the local site of infection. It would have been interesting
to obtain immunohistochemical data on genital tract tissues as this
could provide more information about the local immune response
following infection or re-infection. Immunohistochemistry on genital
tract tissues was performed, but without success. The available
porcine leukocyte markers could not be used on formalin fixed
samples notwithstanding the use of the eBioscience™ IHC antigen
retrieval system (unpublished data). In the future, samples for
immunohistochemistry will be collected in an in house-made zinc
phosphate fixative as it allows optimal antigen retrieval and
visualization of porcine immune cell populations in an “in situ”
histological setting (unpublished data).
Thus, C. trachomatis serovar L2c infection of pigs failed to induce
protective immune responses against reinfection. Similar results were
observed in mice after primary and secondary C. muridarum or C.
trachomatis serovar E infections (74–76). Also, regarding pathology
in women, increases in complications associated with chlamydial
infections, occurred in recurrent infections (77). Both the pathogen
and the host contribute to the outcome of chlamydial infections.
Recently, genome-wide profiling of humoral immunity and pathogen
genes under selection identified immune evasion tactics of C.
trachomatis during ocular infection in children in The Gambia
(78). Children who were susceptible to frequent and/or prolonged
ocular C. trachomatis infection had a less focused antibody response
and data suggested a strategy in whichC. trachomatis presents a large
panel of irrelevant antigens to the human immune system to block or
misdirect protective responses. The latter might also have occurred
during the present study as serum and mucosal antibody titers
against L2c elementary bodies where not particularly high. In
addition, several research groups provided insight in human (76)
and murine (79–82) small non-coding RNA (miRNA) expression
profiles during genital and ocular chlamydial infection and
reinfection and found chlamydia virulence to be associated with
the miRNA expression profile of the host. miRNAs regulate gene
expression as they target mRNAs for degradation, cleavage,October 2020 | Volume 11 | Article 555305
De Clercq et al. Chlamydia trachomatis L2c Infectiontranslational repression or occasional enhancement. SpecificmiRNAs
were involved in the primary infection and reinfection resulting in a
different pathogenesis and outcome in pathology, being more severe
in reinfected mice than in primary infected animals. It might be
interesting to examine this in the pig model.
In conclusion, the pathogenesis of an L2c infection in the porcine
model is rather similar to the pathogenesis of L2c and other C.
trachomatis strain infections in humans. Intravaginal inoculation of
pigs with C. trachomatis L2c resulted in an infection that was
confined to the urogenital tract, where inflammation and
pathology were caused. Re-infection resulted in more severe gross
pathology than primary infection but chlamydial colonization of the
urogenital tract was similar for both the primary infected and re-
infected groups. This indicates that primary infection failed to induce
protective immune responses against re-infection. Indeed, no C.
trachomatis-specific lymphocytes could be detected in the blood
and the lymphoid tissues following infection or re-infection.
However, the cellular immune responses need to be further
investigated by performing immunohistochemical analysis of the
infected urogenital tissues. Hereto, a zinc phosphate fixative will be
used instead of formalin. Nevertheless, anti-chlamydial antibodies
were elicited in sera and vaginal secretions after primary infection,
and re-infection clearly resulted in a secondary systemic andmucosal
antibody response. Apparently, the induced antibody response could
not even partially protect the pigs against re-infection. Our study
supports the notion that the porcine model is an alternative large
animal model for evaluating the immunopathogenesis and evolution
of C. trachomatis infections that will provide data for advancing
therapeutic and vaccine development for humans. Our findings
imply that the pig may function as either an intermediate animal
model between mouse and non-human primates or as a substitute
for the latter during the development of therapeutics and vaccines for
use in human clinical trials.DATA AVAILABILITY STATEMENT
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